Importantly, Lyons et al., using the human transferrin receptor (CD71) as an affinity ligand, could capture diverse cancer cells from blood without prior knowledge of tumor type; capture efficiency and purity depend on CD71 expression, which varies with the cell cycle. Here, TFRC is linked to neoplasm.